Known by many as “the world’s smartest billionaire”, Jim Simons is the founder of the prestigious Renaissance Technologies fund. The fund- one of …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced today that the special committee of independent directors (the “Strategic Review Committee”) has engaged a consulting firm …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced today that it has filed a claim against the Company’s former CEO David Dodd and its former General …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are tumbling nearly 7% in Monday’s trading session, following the news that CEO David Dodd is stepping …
Many investors hope to win big on biotech stocks as shares can skyrocket when there is good news. Maxim analysts explain why there …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that it has been notified by the U.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are up nearly 8% in pre-market trading Friday, after the drug maker announced that it has resubmitted …
Merrimack Pharmaceuticals In a research report sent to investors Wednesday, Cowen’s top analyst Eric Schmidt reiterated a Market Perform rating on shares of Merrimack …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) reported financial and operating results for the first quarter ended March 31, 2017.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are collapsing 60% after underwhelming investors who had been optimistic about the company’s ZoptEC Phase 3 clinical study.
